CD274 and neoplasm: The subsequent phase III KEYNOTE-010 trial which randomized previously treated patients with tumor PD-L1 expression ≥1% to pembrolizumab or docetaxel demonstrated durable survival benefit at the 5 year survival update with pembrolizumab, especially in patients with PD-L1 TPS ≥50% [61].